181 related articles for article (PubMed ID: 38536842)
21. HLA class I binding prediction via convolutional neural networks.
Vang YS; Xie X
Bioinformatics; 2017 Sep; 33(17):2658-2665. PubMed ID: 28444127
[TBL] [Abstract][Full Text] [Related]
22. Graph Neural Network-Based Diagnosis Prediction.
Li Y; Qian B; Zhang X; Liu H
Big Data; 2020 Oct; 8(5):379-390. PubMed ID: 32783631
[TBL] [Abstract][Full Text] [Related]
23. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
Ghorani E; Rosenthal R; McGranahan N; Reading JL; Lynch M; Peggs KS; Swanton C; Quezada SA
Ann Oncol; 2018 Jan; 29(1):271-279. PubMed ID: 29361136
[TBL] [Abstract][Full Text] [Related]
24. Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity.
Kim K; Kim HS; Kim JY; Jung H; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Choi JK
Nat Commun; 2020 Feb; 11(1):951. PubMed ID: 32075964
[TBL] [Abstract][Full Text] [Related]
25. Development of a graph convolutional neural network model for efficient prediction of protein-ligand binding affinities.
Son J; Kim D
PLoS One; 2021; 16(4):e0249404. PubMed ID: 33831016
[TBL] [Abstract][Full Text] [Related]
26. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
27. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
[TBL] [Abstract][Full Text] [Related]
28. A novel candidate disease gene prioritization method using deep graph convolutional networks and semi-supervised learning.
Azadifar S; Ahmadi A
BMC Bioinformatics; 2022 Oct; 23(1):422. PubMed ID: 36241966
[TBL] [Abstract][Full Text] [Related]
29. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
[TBL] [Abstract][Full Text] [Related]
30. Deep learning pan-specific model for interpretable MHC-I peptide binding prediction with improved attention mechanism.
Jin J; Liu Z; Nasiri A; Cui Y; Louis SY; Zhang A; Zhao Y; Hu J
Proteins; 2021 Jul; 89(7):866-883. PubMed ID: 33594723
[TBL] [Abstract][Full Text] [Related]
31. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
32. Drug repositioning of COVID-19 based on mixed graph network and ion channel.
Wang X; Li Q; Liu Y; Du Z; Jin R
Math Biosci Eng; 2022 Jan; 19(4):3269-3284. PubMed ID: 35341251
[TBL] [Abstract][Full Text] [Related]
33. ACME: pan-specific peptide-MHC class I binding prediction through attention-based deep neural networks.
Hu Y; Wang Z; Hu H; Wan F; Chen L; Xiong Y; Wang X; Zhao D; Huang W; Zeng J
Bioinformatics; 2019 Dec; 35(23):4946-4954. PubMed ID: 31120490
[TBL] [Abstract][Full Text] [Related]
34. Multi-type feature fusion based on graph neural network for drug-drug interaction prediction.
He C; Liu Y; Li H; Zhang H; Mao Y; Qin X; Liu L; Zhang X
BMC Bioinformatics; 2022 Jun; 23(1):224. PubMed ID: 35689200
[TBL] [Abstract][Full Text] [Related]
35. Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system.
Paul S; Croft NP; Purcell AW; Tscharke DC; Sette A; Nielsen M; Peters B
PLoS Comput Biol; 2020 May; 16(5):e1007757. PubMed ID: 32453790
[TBL] [Abstract][Full Text] [Related]
36. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
[TBL] [Abstract][Full Text] [Related]
37. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
38. RGN: Residue-Based Graph Attention and Convolutional Network for Protein-Protein Interaction Site Prediction.
Wang S; Chen W; Han P; Li X; Song T
J Chem Inf Model; 2022 Dec; 62(23):5961-5974. PubMed ID: 36398714
[TBL] [Abstract][Full Text] [Related]
39. GNIFdb: a neoantigen intrinsic feature database for glioma.
Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
[TBL] [Abstract][Full Text] [Related]
40. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
